Regeneron’s Ultra-Orphan Arcalyst Hits The Market With A Rare Price
This article was originally published in The Pink Sheet Daily
Executive Summary
$250,000 per year wholesale acquisition cost to treat rare genetic disorder, firm tells “The Pink Sheet” DAILY.